OBJECTIVES: Despite limited scientific evidence for the effectiveness of invasive treatment for intermittent claudication (IC), revascularisation procedures for IC are increasingly often performed in Sweden. This randomised controlled trial compares the outcome after 2 years of primary invasive (INV) versus primary non-invasive (NON) treatment strategies in unselected IC patients. MATERIALS/ METHODS: Based on arterial duplex and clinical examination, IC patients were randomised to INV (endovascular and/or surgical, n = 100) or NON (n = 101). NON patients could request invasive treatment if they deteriorated during follow-up. Primary outcome was maximal walking performance (MWP) on graded treadmill test at 2 years and secondary outcomes included health-related quality of life (HRQL), assessed with Short Form (36) Health Survey (SF-36). RESULTS:MWP was not significantly (p = 0.104) improved in the INV versus the NON group. Two SF-36 physical subscales, Bodily Pain (p < 0.01) and Role Physical (p < 0.05) improved significantly more in the INV versus the NON group. There were 7% crossovers against the study protocol in the INV group. CONCLUSIONS: Although invasive treatment did not show any significant advantage regarding MWP, the HRQL improvements associated with invasive treatment tentatively suggest secondary benefits of this regimen. On the other hand, a primary non-invasive treatment strategy seems to be accepted by most IC patients.
RCT Entities:
OBJECTIVES: Despite limited scientific evidence for the effectiveness of invasive treatment for intermittent claudication (IC), revascularisation procedures for IC are increasingly often performed in Sweden. This randomised controlled trial compares the outcome after 2 years of primary invasive (INV) versus primary non-invasive (NON) treatment strategies in unselected IC patients. MATERIALS/ METHODS: Based on arterial duplex and clinical examination, IC patients were randomised to INV (endovascular and/or surgical, n = 100) or NON (n = 101). NON patients could request invasive treatment if they deteriorated during follow-up. Primary outcome was maximal walking performance (MWP) on graded treadmill test at 2 years and secondary outcomes included health-related quality of life (HRQL), assessed with Short Form (36) Health Survey (SF-36). RESULTS: MWP was not significantly (p = 0.104) improved in the INV versus the NON group. Two SF-36 physical subscales, Bodily Pain (p < 0.01) and Role Physical (p < 0.05) improved significantly more in the INV versus the NON group. There were 7% crossovers against the study protocol in the INV group. CONCLUSIONS: Although invasive treatment did not show any significant advantage regarding MWP, the HRQL improvements associated with invasive treatment tentatively suggest secondary benefits of this regimen. On the other hand, a primary non-invasive treatment strategy seems to be accepted by most IC patients.
Authors: Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh Journal: Circulation Date: 2016-11-13 Impact factor: 29.690
Authors: Annelise L Menêses; Raphael M Ritti-Dias; Belinda Parmenter; Jonathan Golledge; Christopher D Askew Journal: Sports Med Date: 2017-05 Impact factor: 11.136
Authors: George A Antoniou; George S Georgiadis; Stavros A Antoniou; Ragai R Makar; Jonathan D Smout; Francesco Torella Journal: Cochrane Database Syst Rev Date: 2017-04-03
Authors: Maria Teresa B Abola; Jonathan Golledge; Tetsuro Miyata; Seung-Woon Rha; Bryan P Yan; Timothy C Dy; Marie Simonette V Ganzon; Pankaj Kumar Handa; Salim Harris; Jiang Zhisheng; Ramakrishna Pinjala; Peter Ashley Robless; Hiroyoshi Yokoi; Elaine B Alajar; April Ann Bermudez-Delos Santos; Elmer Jasper B Llanes; Gay Marjorie Obrado-Nabablit; Noemi S Pestaño; Felix Eduardo Punzalan; Bernadette Tumanan-Mendoza Journal: J Atheroscler Thromb Date: 2020-07-04 Impact factor: 4.928
Authors: Timothy P Murphy; Matthew R Reynolds; David J Cohen; Judith G Regensteiner; Joseph M Massaro; Donald E Cutlip; Emile R Mohler; Joselyn Cerezo; Niki C Oldenburg; Claudia C Thum; Suzanne Goldberg; Alan T Hirsch Journal: J Vasc Interv Radiol Date: 2013-07-29 Impact factor: 3.464
Authors: Timothy P Murphy; Donald E Cutlip; Judith G Regensteiner; Emile R Mohler; David J Cohen; Matthew R Reynolds; Joseph M Massaro; Beth A Lewis; Joselyn Cerezo; Niki C Oldenburg; Claudia C Thum; Suzanne Goldberg; Michael R Jaff; Michael W Steffes; Anthony J Comerota; Jonathan Ehrman; Diane Treat-Jacobson; M Eileen Walsh; Tracie Collins; Dalynn T Badenhop; Ulf Bronas; Alan T Hirsch Journal: Circulation Date: 2011-11-16 Impact factor: 29.690
Authors: Nicola W Burton; Zanfina Ademi; Stuart Best; Maria A Fiatarone Singh; Jason S Jenkins; Kenny D Lawson; Anthony S Leicht; Yorgi Mavros; Yian Noble; Paul Norman; Richard Norman; Belinda J Parmenter; Jenna Pinchbeck; Christopher M Reid; Sophie E Rowbotham; Lisan Yip; Jonathan Golledge Journal: BMC Public Health Date: 2016-11-09 Impact factor: 3.295
Authors: Bruno Amato; Rita Compagna; Gianni Antonio Della Corte; Giovanni Martino; Tommaso Bianco; Guido Coretti; Roberto Rossi; Antonio Braucci; Giovanni Aprea; Pio Zeppa; Alessandro Puzziello; Claudio Terranova Journal: BMC Surg Date: 2012-11-15 Impact factor: 2.102